TV
A research team from the National Institute of Technology (NIT) Rourkela, led by Prof. Devendra Verma, has developed a bioink made from natural materials for 3D bio printing of bone-like structures.
This breakthrough aims to revolutionize bone grafting and implants, providing a biocompatible and efficient alternative for bone defect treatments.
The research findings have been published in Journal of Biomaterials Science and Carbohydrate Polymers, with co-authors Tanmay Bharadwaj and Shreya Chrungoo. The team has also secured a patent (Patent No. 562791, Application No. 202331054665, granted on March 18, 2025) for the technology.
Addressing Challenges in Bone Repair
Current bone grafting techniques involve using bone from donors or metal implants, both of which have significant drawbacks, including pain, rejection risks, and complications over time. While 3D bioprinting offers an alternative, existing bioinks require extended preparation periods before implantation, limiting their clinical feasibility.
Innovative Features of the Bioink
The newly developed bioink remains liquid at room temperature but rapidly gels upon exposure to body temperature and pH, allowing direct printing onto injury sites instead of requiring pre-formed implants. This advancement simplifies treatment and accelerates healing.
Composed of chitosan, gelatin, and nanohydroxyapatite, the bioink closely mimics natural bone components, promoting stem cell growth and bone regeneration. It also includes specialized nanofibers that enhance cell attachment and proliferation, essential for effective healing.
Potential Applications & Future Prospects
Funded by the Department of Health Research (DHR), Government of India, this bioink has promising applications in orthopedic and reconstructive surgeries, particularly for treating large bone defects and facial reconstructive procedures. Its adaptability makes it ideal for irregularly shaped bone injuries, offering a personalized approach to treatment.
The research team now plans to test the bioink in animal models and develop a scalable production process for clinical trials in a Good Manufacturing Practices (GMP) facility. To commercialize the technology, the team has established a startup, Quixotix Bioprinting Pvt. Ltd.
Prof. Verma emphasized, “This research contributes to the growing field of 3D bioprinting by offering a natural, easy-to-use bioink capable of supporting bone regeneration. Further studies and clinical trials will determine its real-world effectiveness, paving the way for its use in orthopedic and reconstructive surgery.”
